{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T16:50:04Z","timestamp":1791651004963,"version":"4.3.4"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:00:00Z","timestamp":1791590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:00:00Z","timestamp":1791590400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatology"],"abstract":"<jats:p>Introduction: Real-world data on secukinumab use in Thai patients with psoriasis is limited. This study evaluates its effectiveness and safety in routine clinical practice. Methods: The PROMPT study is an ongoing, multicenter, 2-year observational study involving patients with moderate to severe plaque psoriasis (PsO), active psoriatic arthritis (PsA), or ankylosing spondylitis (AS) treated with secukinumab. This interim analysis reports one-year outcomes in patients with plaque PsO. Results: A total of 101 patients with moderate to severe plaque PsO were included. The one-year secukinumab retention rate was 80% (95% CI: 75\u201388%). The most common reasons for discontinuation were financial constraints and lack of reimbursement. Effectiveness outcomes showed a significant reduction in psoriasis area and severity index (PASI) scores, with a mean percentage change of -84% (95% CI: -88 to -79%), and 77 patients achieved PASI 75. Physician\u2019s global assessment (PGA) scores also improved significantly, with a median score of 1.0 at 12 months. Health-related quality of life (HRQoL) improved, with a mean utility score increase of 0.2 (95% CI: 0.1\u20130.2) and a mean DLQI score reduction of -80% (95% CI: -85 to -75%). Only three patients reported adverse drug events, with no serious adverse events observed. Conclusion: Secukinumab demonstrated one-year retention comparable to previous real-world studies, with a favorable safety profilein Thai patients with moderate to severe plaque psoriasis. It significantly improved disease severity and HRQoL in real-world clinical settings.<\/jats:p>","DOI":"10.1159\/drm\/ackag023","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T11:49:48Z","timestamp":1791373788000},"source":"Crossref","is-referenced-by-count":0,"title":["One-Year Real-Life Data from Thai Patients with Moderate to Severe Plaque Psoriasis Treated with Secukinumab \u2013 Outcomes from the PROMPT Study"],"prefix":"10.1159","author":[{"given":"Pravit","family":"Asawanonda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leena","family":"Chularojanamontri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mati","family":"Chuamanochan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warayuwadee","family":"Amornpinyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Padcha","family":"Pongcharoen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supapat","family":"Laodheerasiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bensachee","family":"Pattamadilok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charoen","family":"Choonhakarn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"siripan","family":"sangmala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisa","family":"Pretikul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Metavee","family":"Boonsiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naruemon","family":"Sangob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ploysyne","family":"Rattanakaemakorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2026,10,10]]},"container-title":["Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/drm\/ackag023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T16:01:52Z","timestamp":1791648112000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/drm\/ackag023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,10]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/drm\/ackag023","archive":["Portico"],"relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.6084\/m9.figshare.34237026","asserted-by":"subject"}]},"ISSN":["1018-8665","1421-9832"],"issn-type":[{"value":"1018-8665","type":"print"},{"value":"1421-9832","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,10]]}}}